Adding Atezolizumab Improves Survival in Advanced Cervical Cancer
First-line treatment with the anti-PD-L1 inhibitor atezolizumab (Tecentriq) combined with bevacizumab (Avastin) and platinum-based chemotherapy significantly improved survival in patients with metastatic or recurrent cervical cancer, according to results of the phase III BEATcc trial. The median progression-free survival (PFS) was 13.7 months with added atezolizumab compared with 10.4 months with the standard bevacizumab plus […]
Add-on Pembrolizumab Tied to Good QoL in Women With Advanced Cervical Cancer
PHOENIX — The addition of pembrolizumab (Keytruda) to chemotherapy, with or without bevacizumab (Avastin), in women with persistent, recurrent, or metastatic cervical cancer was linked with better quality of life (QoL), a researcher reported. Patient-reported outcomes (PRO) from the KEYNOTE-826 trial showed that changes from baseline in QLQ-C30 global health status (GHS)/QoL scores — a […]
Practice-Changing Study in Advanced Cervical Cancer
Adding pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) significantly slowed progression of metastatic cervical cancer and improved overall survival (OS), investigators in a randomized trial concluded. Median progression-free survival (PFS) improved from 8.2 months with chemotherapy plus or minus bevacizumab (Avastin) to 10.4 months with the addition of the PD-1 inhibitor. Comparison of […]